Combination pharmaceutical composition and methods of treating functional diseases or conditions of gastrointestinal tract

A composition and gastrointestinal technology, which can be used in drug combinations, pharmaceutical formulations, nervous system diseases, etc., and can solve problems such as the inability to ensure the efficacy of functional bowel disorder treatment.

Inactive Publication Date: 2013-05-08
奥列格·伊里奇·爱泼斯坦
View PDF6 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, this pharmaceutical preparation does not ensure sufficient therapeutic efficacy for functional bowel disorders in all cases

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Combination pharmaceutical composition and methods of treating functional diseases or conditions of gastrointestinal tract
  • Combination pharmaceutical composition and methods of treating functional diseases or conditions of gastrointestinal tract
  • Combination pharmaceutical composition and methods of treating functional diseases or conditions of gastrointestinal tract

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0277] The effect of the following antibodies was investigated in three experimental studies: i) very low doses of anti-histamine antibody (His Ab), affinity purified with antigen, by high dilution (100 12 、100 30 and 100 200 and ii) a complex (S100Ab+TNF Ab+His Ab) of the following antibodies: a) a very low dose of anti-histamine antibody (His Ab), with antigen Affinity purification was performed by high dilution (100 12 、100 30 and 100 200 diluents (mixture of C12, C30 and C200)), b) a very low dose of anti-S-100 protein antibody (S-100Ab), affinity purified with antigen, by high dilution of the initial matrix solution (100 12 、100 30 and 100 200 Dilutions (mixture of C12, C30 and C200)), and c) very low doses of anti-tumor necrosis factor alpha antibody (TNF Ab), affinity purified with antigen, by high dilution (100 12 、100 30 and 100 200 Diluents (mixture of C12, C30 and C200)) obtained.

[0278] Study 1: Effects on the excretory function of the mouse gastrointes...

Embodiment 2

[0301] Anti-human tumor necrosis factor alpha polyclonal rabbit antibody (TNF Ab), anti-brain-specific protein S-100 polyclonal rabbit antibody (S100Ab) and anti-histamine polyclonal rabbit antibody (His The aqueous-alcoholic solution (6 mg / tablet) of Ab) impregnated the lactose carrier to prepare 300 mg tablets. The components used for impregnation are passed through the initial matrix solution with a concentration of 2.5 mg / ml 100 12 、100 30 、100 200 Obtained by a high dilution of one-fold (a mixture of hundred-fold homeopathic dilutions C12, C30 and C200). For the control group, 300 mg of other tablets were used, saturated with a very low dose of a water-alcoholic solution (3 mg / tablet) of an antihistamine polyclonal rabbit antibody (FisAb) purified with antigen, which Pass the initial matrix solution 100 at a concentration of 2.5 mg / ml 12 、100 30 、100 200 Obtained by a high dilution of one-fold (a mixture of hundred-fold homeopathic dilutions C12, C30 and C200).

[...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The preset invention provides a combination pharmaceutical composition comprising a) an activated-potentiated form of an antibody to a S-100 protein, b) an activated-potentiated form of an antibody to histamine, and c) an activated-potentiated form of an antibody to TNF-alpha. Various embodiments and variants are provided. The present invention provides a method of treating a disease or condition of functional etiology of the gastrointestinal tract said method comprising administering to a patient in need thereof a combination pharmaceutical composition comprising a) an activated-potentiated form of an antibody to a histamine, b) an activated-potentiated form of an antibody to S-100 protein and c) an activated-potentiated form of an antibody to TNF-alpha. Various embodiments and variants are provided.

Description

technical field [0001] The invention relates to a compound pharmaceutical composition and a method for treating functional diseases or diseases of the gastrointestinal tract. Background technique [0002] The present invention relates to the field of medicine and can be used for the treatment of functional disorders or conditions of the gastrointestinal tract (GIT), including irritable bowel syndrome (irritable bowel syndrome) and GIT (including intestinal) motor-evacuator dysfunction. [0003] The treatment of erosive and inflammatory diseases of the gastrointestinal tract based on very low doses of histamine antibodies is known in the art (RU 2197266C1). However, this pharmaceutical preparation does not ensure in any case a sufficient therapeutic efficacy for functional bowel disorders. [0004] Dr. Oleg I. Epshtein has discovered the therapeutic effect of an extremely diluted form (or very low form) of antibodies (activated potentiated form) enhanced by homeopathic techn...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K39/395C07K16/18C07K16/24A61K41/00A61P1/00
CPCA61K39/395C07K16/24C07K16/241C07K16/18A61K41/0004A61K2039/507A61P1/00A61P1/06A61P1/10A61P1/12A61P1/14A61P25/00A61P43/00A61K2300/00C07K16/28
Inventor 奥列格·伊里奇·爱泼斯坦
Owner 奥列格·伊里奇·爱泼斯坦
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap